Frontier IP Group PLC has announced its 4.26% stake in DiaGen Ai Inc, a Canadian company focused on AI-driven protein and peptide design for medical applications. DiaGen has entered into a Technology Evaluation Agreement with Frontier IP's portfolio company, The Vaccine Group (TVG). DiaGen, formerly known as Proteic Bioscience Inc, was founded in 2021 to develop a proprietary AI engine for protein design, drug discovery, and diagnostics for health, wellness, longevity, and precision medicine.

The collaboration between DiaGen and TVG aims to develop novel and better vaccines for use in animals. The initial focus will be on broadly-protective vaccine candidates for a disease caused by a virus that mutates frequently, making it challenging to develop effective vaccines. Paolo Lobo, DiaGen President, expressed excitement about integrating their proprietary AI capabilities into the Veterinary sector to optimize protein structures for expression and immune stimulation, complementing TVG's expertise in advancing their vaccine pipeline.

Jeremy Salt, TVG Chief Executive, highlighted that the partnership with DiaGen will bring strong complementary AI approaches to develop novel and improved vaccines. The collaboration will utilize TVG's herpesviral vector delivery system to deliver optimal antigens designed by DiaGen for expression in animal patients. This partnership represents a significant development in TVG's ability to address key gaps in the veterinary vaccine market.

Frontier IP Chief Executive Neil Crabb emphasized the benefits of their clusters approach, where expertise and know-how can be shared profitably between companies. He expressed anticipation for the successful results of this collaboration. Frontier IP unites science, finance, and industry by identifying strong intellectual property and accelerating its development through a range of commercialization services. The Group aims to build and grow a portfolio of equity stakes and license income by taking an active involvement in spin-out companies, including support for fundraising and collaboration with relevant industry partners at an early stage of development.

This announcement is a RNS Reach announcement, a non-regulatory press release distribution service aimed at assisting listed and unlisted companies to distribute media-only news releases into the public domain. Regulatory information would be disseminated as an RNS regulatory announcement and not on Reach.

Frontier IP Group PLC's collaboration with DiaGen and TVG demonstrates its commitment to leveraging AI-driven solutions for the development of innovative vaccines, showcasing the company's dedication to advancing healthcare and biotechnology.